Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Rodgers

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Gynecologic Oncology|October 17, 2016
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysisAmanda N Fader, James Java, Meaghan Tenney, et al.
Circulation|August 24, 2014
CD82 restrains pathological angiogenesis by altering lipid raft clustering and CD44 trafficking in endothelial cellsQuan Wei, Feng Zhang, Mekel M Richardson, et al.
Gynecologic Oncology|October 7, 2025
Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263)Dana M Chase, Helen Q Huang, Wei Deng, et al.
Lancet (London, England)|February 6, 2022
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trialDavid M Gershenson, Austin Miller, William E Brady, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancerRobert L Hollis, Austin Miller, Heather A Lankes, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Gynecologic Oncology|October 17, 2016
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysisAmanda N Fader, James Java, Meaghan Tenney, et al.
Circulation|August 24, 2014
CD82 restrains pathological angiogenesis by altering lipid raft clustering and CD44 trafficking in endothelial cellsQuan Wei, Feng Zhang, Mekel M Richardson, et al.
Gynecologic Oncology|October 7, 2025
Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263)Dana M Chase, Helen Q Huang, Wei Deng, et al.
Lancet (London, England)|February 6, 2022
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trialDavid M Gershenson, Austin Miller, William E Brady, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancerRobert L Hollis, Austin Miller, Heather A Lankes, et al.
Pageof 5